Home/Galectin Therapeutics/Joel Lewis

JL

Joel Lewis

President & CEO

Galectin Therapeutics

Therapeutic Areas

Chronic Liver Disease Oncology

Galectin Therapeutics Pipeline

Drug	Indication	Phase
Belapectin (GR-MD-02)	MASH Cirrhosis with Portal Hypertension	Phase 2b/3

Leadership Team at Galectin Therapeutics

Elisabeth (Lisa) R. G. Wright, CPA

Chief Financial Officer

Pol F. Boudes, MD

Chief Medical Officer

Henry Brem, M.D.

Board of Directors

View full Galectin Therapeutics profile